Profile data is unavailable for this security.
About the company
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Bites, Calci-Tab, Candacort, Candacort Minipak, Candaderm, Coco-Scalp, Combolieve, Cromo-Fresh, Dry skin, Eczema, Emulsifying Ointment BP, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE and others.
- Revenue in NZD (TTM)174.51m
- Net income in NZD11.02m
- Incorporated1997
- Employees100.00
- LocationAFT Pharmaceuticals LtdLevel 1, 129 Hurstmere RoadAUCKLAND 0622New ZealandNZL
- Phone+64 94880232
- Fax+64 94880234
- Websitehttp://www.aftpharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cuorips Inc | 433.77k | -6.51m | 307.17m | 46.00 | -- | 4.63 | -- | 708.16 | -76.49 | -76.49 | 5.13 | 766.30 | 0.0081 | 3.93 | 39.73 | 867,130.40 | -12.10 | -- | -12.39 | -- | 45.79 | -- | -1,500.91 | -- | 35.89 | -- | 0.00 | -- | 175.12 | -- | -20.45 | -- | -- | -- |
| Wuhan YZY Biopharma Co Ltd | -21.30bn | -21.30bn | 307.60m | 123.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.50 | -- | -- | -- |
| Ngl Fine Chem Ltd | 63.25m | 7.58m | 310.11m | 343.00 | 40.89 | -- | 31.25 | 4.90 | 61.52 | 61.52 | 513.13 | -- | -- | -- | -- | 9,241,813.00 | -- | 15.74 | -- | 20.73 | 53.94 | 45.27 | 11.99 | 13.43 | -- | 34.92 | -- | 3.47 | -12.42 | 19.17 | -58.92 | 10.23 | 5.65 | -- |
| Jacobio Pharmaceuticals Group Co Ltd | 14.60m | -82.54m | 313.66m | 301.00 | -- | 1.27 | -- | 21.49 | -0.5013 | -0.5013 | 0.0887 | 1.46 | 0.0419 | -- | 5.21 | 227,719.70 | -23.66 | -45.76 | -26.86 | -49.30 | 5.04 | -- | -565.36 | -372.22 | -- | -- | 0.1636 | -- | -33.66 | -- | 3.43 | -- | 19.18 | -- |
| AFT Pharmaceuticals Ltd | 174.51m | 11.02m | 314.60m | 100.00 | 28.55 | 4.26 | 25.03 | 1.80 | 0.1051 | 0.1051 | 1.66 | 0.7048 | 1.22 | 2.00 | 5.67 | 1,745,050.00 | 7.73 | 10.00 | 12.48 | 15.59 | 45.98 | 46.12 | 6.31 | 8.22 | 0.8372 | 5.99 | 0.3566 | 0.00 | 20.20 | 14.05 | -46.32 | -- | 26.32 | -- |
| StemRIM Inc | 25.56m | 1.95m | 317.67m | 44.00 | 138.76 | 2.97 | -- | 12.43 | -0.1097 | -0.1097 | 37.43 | 159.71 | 0.2453 | -- | -- | 53,409,090.00 | 1.87 | -6.71 | 1.89 | -6.83 | -- | -- | 7.63 | -45.80 | 78.90 | 652.72 | 0.00 | -- | 10,128.06 | 63.68 | 108.64 | -- | -- | -- |
| Sinphar Pharmaceutical Co Ltd | 152.63m | 19.33m | 317.94m | 984.00 | 16.48 | 1.99 | 10.57 | 2.08 | 2.23 | 2.23 | 17.64 | 18.47 | 0.4765 | 2.37 | 6.03 | -- | 5.74 | -0.0147 | 7.76 | -0.0203 | 36.83 | 37.49 | 12.04 | -0.0344 | 1.50 | 16.24 | 0.364 | 79.70 | 3.72 | 5.98 | 67.01 | 111.88 | 3.31 | 58.49 |
| Shaanxi Kanghui Pharmaceutical Co Ltd | 135.24m | -16.11m | 319.91m | 828.00 | -- | 1.42 | -- | 2.37 | -0.7018 | -0.7018 | 5.89 | 9.84 | 0.289 | 2.23 | 3.02 | 710,868.00 | -4.51 | 1.41 | -6.35 | 1.71 | 30.41 | 45.74 | -15.60 | 4.48 | 0.8839 | -2.79 | 0.4034 | 32.34 | 11.01 | 6.01 | -272.84 | -- | 107.49 | -- |
| SanBio Co Ltd | 0.00 | -28.76m | 320.92m | 29.00 | -- | 10.46 | -- | -- | -40.50 | -40.50 | 0.00 | 41.11 | 0.00 | -- | -- | 0.00 | -43.74 | -42.00 | -52.38 | -48.88 | -- | -- | -- | -4,790.72 | -- | -- | 0.1923 | -- | -- | -- | 52.44 | -- | 53.94 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Accident Compensation Corp.as of 30 Apr 2023 | 4.86m | 4.63% |
| Guardians of New Zealand Superannuationas of 30 Apr 2023 | 1.69m | 1.62% |
| FCA Corp.as of 31 Mar 2024 | 46.00k | 0.04% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 39.19k | 0.04% |
| Acadian Asset Management LLCas of 30 Sep 2023 | 4.43k | 0.00% |
